Compare UFPT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | MNKD |
|---|---|---|
| Founded | 1963 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2004 |
| Metric | UFPT | MNKD |
|---|---|---|
| Price | $204.79 | $2.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $289.00 | $8.64 |
| AVG Volume (30 Days) | 187.1K | ★ 6.4M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | N/A |
| EPS | ★ 8.75 | 0.02 |
| Revenue | ★ $602,797,000.00 | $348,966,000.00 |
| Revenue This Year | $8.33 | $33.40 |
| Revenue Next Year | $5.59 | $16.48 |
| P/E Ratio | ★ $23.93 | $140.50 |
| Revenue Growth | 19.50 | ★ 22.23 |
| 52 Week Low | $178.26 | $2.52 |
| 52 Week High | $274.93 | $6.51 |
| Indicator | UFPT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 23.92 |
| Support Level | $188.43 | N/A |
| Resistance Level | $206.13 | $6.08 |
| Average True Range (ATR) | 12.35 | 0.37 |
| MACD | -0.82 | -0.09 |
| Stochastic Oscillator | 16.36 | 8.26 |
UFP Technologies Inc is a designer and custom manufacturer of components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics for the medical market. The company manufactures its products by converting raw materials using laminating, molding, radio frequency and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.